The U.S. Food and Drug Administration announced it will merge its fragmented adverse-event reporting systems into a single platform, the Adverse Event Monitoring System (AEMS). Agency officials say consolidation will centralize reports for drugs, vaccines and other regulated products and reduce operating costs while providing a unified view for regulators. The move unifies legacy databases that have long complicated cross-center surveillance and signals analysis. FDA presentations emphasize improved data access and reduced duplication, but acknowledge that AEMS will inherit limitations of passive reporting: entries are unverified and cannot by themselves establish causation or incidence. Companies, clinicians and patient groups should expect changes to reporting workflows and post-market commitments as the agency phases in AEMS. The consolidated system could streamline cross-product safety reviews and post-market study coordination, but stakeholders will be watching how the FDA manages data quality, transparency and timelines for the switchover.